CorMedix (CRMD) Convertible Debt (2012 - 2019)

CorMedix (CRMD) reported Convertible Debt of $6.7 million for Q2 2019, up 4.77% sequentially from $6.4 million in Q1 2019.

CorMedix (CRMD) Convertible Debt (2012 - 2019) Analysis & Trends

CorMedix (CRMD) has 4 years of Convertible Debt data on file, last reported at $6.7 million in Q2 2019.

For the quarter ending Q2 2019, Convertible Debt changed N/A year-over-year to $6.7 million; the trailing twelve-month figure through Jun 2019 stood at $6.7 million (changed N/A YoY), and the FY2018 full-year result was $6.1 million, changed N/A from the prior year.
Convertible Debt grew to $6.7 million in Q2 2019, from $6.4 million in the prior quarter.
In the past five years, Convertible Debt ranged from a high of $6.7 million in Q2 2019 to a low of $6.1 million in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	CorMedix	546.82 Mn	391.62 Mn	107.31 Mn

Download Data